Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health

Executive Summary

Recently created biotech Myovant has floated on the New York Stock Exchange to raise capital to progress its two lead candidate therapies; one for women's health conditions and another for prostate, and says Pfizer's sizable stake in the IPO reflects rising interest in these therapy areas.


Related Content

Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
What's Next For Roivant? It's Not More Publicly Traded "Vants"
Fortress Biotech: A Drug Financing Experiment Expands
Myovant On Path To Women’s Health Leadership, CEO Says
Start-Up Quarterly Statistics, Q4 2016
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Takeda Continues To Shed Pipeline Assets In Roivant Deal


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts